AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Amer Sports is successfully executing a premiumization strategy that has accelerated revenue growth to 32.1% as of 2026Q1 while simultaneously expanding gross margins to 59.9%. The company has significantly de-risked its capital structure by reducing total deb...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 32.1% in 2026Q1, supported by a structural expansion in gross margins from 52.0% in 2023Q4 to 59.9%.
The bullish thesis highlights Amer Sports' growth driven by the Chinese market, indicating strong potential for revenue expansion.
Amer Sports benefits from robust brand performance, which supports sustained demand and market positioning.
The stock is perceived as undervalued, presenting an attractive investment opportunity based on current metrics.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 18, 2026 | $0.22+108.3% vs $0.11 | $1.6B+6.0% vs $1.5B |
Q2 2026 May 19, 2026 | $0.38+24.1% vs $0.31 | $1.9B+5.9% vs $1.8B |
Q1 2026 Feb 24, 2026 | $0.31+11.0% vs $0.28 | $2.1B+5.3% vs $2.0B |
Q4 2025 Nov 18, 2025 | $0.33+31.0% vs $0.25 | $1.8B+2.1% vs $1.7B |
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Lakeland Industries (NASDAQ: LAKE - Get Free Report) and Amer Sports (NYSE: AS - Get Free Report) are both consumer discretionary companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Profitability This table compares Lakeland Industries and
Amer Sports, Inc. (AS) Analyst/Investor Day Transcript

Amer Sports demonstrates strong growth through its premium Arc'teryx and Salomon brand platforms. The company faces significant risks from trade policy volatility and potential tariff impacts.
Benchmark AS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amer Sports, Inc. (AS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.08 | $15.66B | 35.63 | 26.68% | 6.51% | 7.89% | — | |
| $35.15 | $52.02B | 16.74 | 0.19% | 6.7% | 22% | — | |
| $4.64 | $1.98B | -4.00 | -3.86% | -9.96% | -32.12% | — | |
| $57.69 | $2.95B | 17.81 | 0.84% | 6.05% | 12.58% | — | |
| $14.41 | $5.67B | 22.52 | 1.06% | 2.88% | 15.95% | — | |
| $362.96 | $22.14B | 24.02 | 14.63% | 11.76% | 35.64% | — |
Amer Sports, Inc. (AS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amer Sports, Inc. (AS) stock FAQ — growth, dividends, profitability & financials explained
Amer Sports, Inc. (AS) reported $7.44B in revenue for fiscal year 2025. This represents a 204% increase from $2.45B in 2020.
Amer Sports, Inc. (AS) grew revenue by 26.7% over the past year. This is strong growth.
Yes, Amer Sports, Inc. (AS) is profitable, generating $546.4M in net income for fiscal year 2025 (6.5% net margin).
Amer Sports, Inc. (AS) has a return on equity (ROE) of 7.9%. This is below average, suggesting room for improvement.
Amer Sports, Inc. (AS) generated $686.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.